Skip to main content
Stocktwits

WATCHLIST

Featured

DISCORD | #Travisten-group: A coterie of traders

My name is Nathan Ambersley (group director), I've been trading since 2009 and in this Discord group, we'll discuss my process of finding stocks and how I enter and exit positions. If you're looking for a simple to understand, consistent trading/scalping strategy, look no further. The fee is $140 monthly, you can email contact@travisten.com to receive an invoice and Discord invite.

You can follow me for FREE on, Stocktwits @Travisten,  Twitter @TRADERLIFEno1, Tradingview @Travisten, to get an idea of how I trade, I primarily trade Nasdaq.

Complete Taxation Guide to Canadian Real Estate Taxation

  You may have already figured out that there are a few myths passed on in the real estate taxation world. Most accountants tell you incorporating is not beneficial but you always wonder why so many real estate investors incorporate their portfolio anyway. You may wonder what the different types of are available as real estate investors and whether you would still have any money left after the Tax Man grabs his share.

Comments

Popular posts from this blog

Dr Martin Luther King Jr. | A Testament of Hope: The Essential Writings and Speeches

Noblechairs

Upgrade your workspace

$OGI Organigram shares soar 30% after sales double in first quarter

$RBZ Reebonz Holding Limited | NASDAQ

Reebonz Holding Ltd is a Singapore based that operates in the online luxury market. The company through its online marketplace and platform is engaged in buying and selling of new and pre-owned luxury products in the Asia Pacific region including Singapore, Malaysia, Indonesia, Thailand, the Philippines, Vietnam, Hong Kong, South Korea, Taiwan, Australia, and New Zealand.
https://www.reebonz.com/

What's a Locked or Crossed Market? | Ally Invest

How does after-hours trading impact stock price quotes? | Ally Invest

$TCON TRACON Pharmaceuticals Inc. | NASDAQ

TRACON Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration (wet AMD). The company's pipeline consists of product candidates such as TRC105, TRC102, TRC253, TRC694, and TRC205. The lead product TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or programmed cell death protein 1 pathway.
http://www.traconpharma.com/